[The role of antiarrhythmic surgery in 2004]

G M Guiraudon1

  • 1The Robarts Research Institute, University of Western Ontario, London, Canada. gguiraud@uwo.ca

Archives Des Maladies Du Coeur Et Des Vaisseaux
|December 22, 2004
PubMed

Insights

Surgery for atrial fibrillation, particularly the Corridor III operation, offers high efficacy and long-term control. Minimally invasive techniques and concomitant procedures improve outcomes, but require further validation.

Area of Science:

  • Cardiac Surgery
  • Electrophysiology
  • Cardiovascular Research

Context:

  • Surgery for cardiac arrhythmias primarily targets atrial fibrillation.
  • Left atrial appendage exclusion during surgery mitigates thrombo-embolic event risk.
  • Minimally invasive techniques are increasingly adopted for atrial fibrillation surgery.

Purpose:

  • To evaluate the efficacy and long-term control of the Corridor III surgical operation for lone atrial fibrillation.
  • To assess the impact of concomitant atrial fibrillation surgery with other cardiac repairs.
  • To explore future directions for atrial fibrillation surgery, emphasizing efficacy, safety, and cost-effectiveness.

Summary:

  • The Corridor III operation demonstrates high efficacy and long-term arrhythmia control for lone atrial fibrillation when performed correctly.
  • Failures are linked to incomplete block lines or exclusion, highlighting the need for postoperative electrophysiology testing.
  • Concomitant atrial fibrillation surgery with other cardiac procedures yields excellent results without increased risk.

Impact:

  • Surgical interventions for atrial fibrillation, especially when minimally invasive, can achieve high efficacy and long-term control.
  • Future developments require atrial surgery to maintain low morbidity, demonstrate cost-effectiveness, and undergo rigorous clinical trials.
  • Improved surgical rationales and documented clinical benefits in survival, thrombo-embolic prevention, and quality of life are anticipated.

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...